Mesothelioma is a cancerous disease that affects the serous linings of various internal organs in the human body. Among them, the lungs, heart and the stomach are the mostly affected. It is estimated that each year, 2,000 new cases of Mesothelioma are reported. T...

Chemotherapy is often used in conjunction with surgery and/or radiation treatments for cancer. Chemotherapy can be used by itself in cases where the patient is not a candidate for surgery. In 2004, pemetrexed, also commercially known by its brand name Alimta, became t...

間皮瘤是與å°�石棉纖維的暴露連接在案件的70 到百分之80 的癌症。 全國巨蟹星座學院作為"癌症的一個罕見的形å¼�定義惡性間皮瘤... 癌症的疾病(惡性) 細胞被發ç�¾åœ¨sac 排行胸å�£(肋膜), 胃腸洞(腹膜的) 襯è...

Mesothelioma clinical trial is done in across the globe due to the intensity of the problem associated with the disease.A clinical trial is a research study undertaken on volunteers with the intention of finding various types of cures or treatments for mesothelioma or...

Mesothelioma is very similar to other cancers in respect to treatment. Mesothelioma patients have three treatment options available to them: chemotherapy, radiation, or surgery. These treatments are typically performed in conjunction with one another to ensure the mos...

What is Mesothelioma Asbestos?Mesothelioma is a rare form of cancer caused by exposure to asbestos. Asbestos is a naturally-occurring fiber, that, when released into the air, can be inhaled or swallowed. Asbestos has no smell or taste, and asbestos fibers are so tiny ...

The Food and Drug Administration (FDA) recently approved Alimta (pemetrexed disodium) for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma. It is the first drug approved for this condition.Mesothelioma treatment can i...

Conventional therapies are of little use in Mesothelioma Treatment. The survival time after diagnosis is around 6 to 12 months. The spread of malignant cells to the underlying tissue and other organs in the pleural cavity, the pleural cavity encouraging local metastas...

In order to try and find an effective treatment and cure for mesothelioma, clinical trials have been a vital part of the treatment process. These trials, carried out at institutions and hospitals all over the country, are extensive tests to determine the efficiency an...

Mesothelioma is a disease that affects cancer serous linings of various internal organs of the human body. These include the lungs, heart and the stomach are the most affected.It is estimated that each year, 2000 new cases of mesothelioma are reported. Patients with t...

Several new mesothelioma treatments are being developed. Researches mostly revolve around developing new treatments or improving upon the traditional treatments. Hopes are high for mesothelioma patients as new chemotherapy agents and combinations of agents are giving ...

What is Asbestos?Asbestos is a term for several commonly found fibrous magnesium-silicate minerals. Due to their durable and versatile nature, asbestos materials were used widely in construction and manufacturing for most of the 20th century. Today, it is widely under...

An October 2005 report states that a new method that assists diagnosis of pleural mesothelioma is to measure the presence of osteopontin in blood. Pleural Mesothelioma provides detailed information on Malignant Diffuse Pleural Mesothelioma, Malignant Pleural Mesoth...

Tokyo, Japan, July 6, 2006 - (JCN) - Bristol-Myers has filed an application for an additional indication of Briplatin Injection, its proprietary anti-tumor agent, with the Ministry of Health, Labor and Welfare. The company is currently seeking approval for a combina...

Tokyo, Japan, June 28, 2006 - (JCN) - Oki Environment Technologies, a wholly owned subsidiary of Oki Electric Industry, announced on June 27 that it has released the Kaiteki My Car (OZ-1), an ozone generator for use in automobiles that was developed in collaboration ...

Kyoto, Japan, June 26, 2006 - (JCN) - Kyocera has introduced high-efficiency turbo refrigerators in the company's major plants and research laboratory in Japan. The measures will be undertaken starting in July as part of the company's initiatives to prevent global wa...

A 48-year-old male with history of hypertension, S/P thoracic aneurysm and aortic valve repair, presented with increasing shortness of breath. A chest CT showed extensive pleural thickening, right pneumothorax with pulmonary vein compression and left mediastinal ...

Tokyo, Japan, June 28, 2006 - (JCN) - Eli Lilly Japan has filed an application for pemetrexed and cisplatin cisplatin /cis·plat·in/ (sis´plat-in) DDP; a platinum coordination complex capable of producing inter- and intrastrand DNA crosslinks; used as an antin...

Business Editors/Health/Medical Writers INDIANAPOLIS--(BUSINESS WIRE)--Oct. 8, 2003 Lilly Initiative Provides Investigational Agent Free of Charge for Medically Eligible Patients with Mesothelioma mes·o·the·li·o·mas or mes·o·the·li·o·ma·ta (-m-t  I...

BOSTON -- Point Therapeutics, Inc. (NASDAQ: POTP) today provided a clinical update on its current clinical program which includes two Phase 3 trials in Stage IIIB/IV non-small cell lung cancer (NSCLC) and a Phase 2 trial in Stage IV pancreatic cancer. Phase 3 ...

BOSTON -- Point Therapeutics, Inc. (NASDAQ: POTP) today reported financial results for the fiscal quarter and nine months ended September 30, 2005.In the third quarter of 2005, Point reported a net loss of $6,716,000 or $0.29 per share, compared with a net loss of ...

BASINGSTOKE, England, November 1 /PRNewswire/ -- ...

Business Editors, Health & Medical Writers ...

Results from a Phase III study, published in the Journal of Clinical Oncology, demonstrate that Eli Lilly's Alimta (pemetrexed), in combination with cisplatin, is associated with superior survival duration compared with cisplatin alone in the treatment of patients...

ELI LILLY and Company reported positive Phase III trial data on Alimta (pemetrexed) in mesothelioma. Billed as a successor to its flagship oncology drug Gemzar (gemcitabine), analysts project peak sales for Alimta at nearly $1 billion. ...

NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that significant scientific data on ERBITUX([R]) (cetuximab) will be presented at the American Societ...

SOUTH SAN FRANCISCO, Calif. -- Completed Phase I Results to Be Presented at American Society of Clinical Oncology (ASCO) Meeting to Be Held June 2-6, 2006 in Atlanta ...

Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability. Chattopadhyay S, Tamari R, Min SH, et al. Oncologist 2007; 12:808-81 5. ...